Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment option for myeloid neoplasms (MN). In rare cases, the development of de novo hematologic malignancies derived from cells of donor origin, named donor cell hematologic neoplasm (DCHN), can occur.1,2 Although some mechanisms have been suggested, the etiological factors and mechanisms involved in DCHN onset remain elusive. Moreover, DCHN is an extremely unusual allo-HSCT complication. But it provides a useful in vivo model to understand the genomic processes driving the leukemic transformation of donor stem cells. This study collects the first large cohort in which whole exome sequencing (WES) was performed in several post-transplant bone marrow (BM) samples from DCHN patients and their donors.
A cohort of seven patients (Table 1 and Online Supplementary Appendix) recruited from three hospitals belonging to the Spanish Group of Hematopoietic Transplantation (GETH) and their donors were included. The study included 32 BM samples from different time points after allo-HSCT (Online Supplementary Figure S1) as well as one peripheral blood (PB) sample from each donor. The research protocol was approved by the Ethics Committee of Gregorio Marañón General University Hospital. The study WES workflow is summarized in Figure 1 and the Online Supplementary Methods.
The results of the analysis of the mutational profiles obtained from the sequential post-HSCT samples demonstrated high intra-tumor genetic heterogeneity and clonal dynamics for all seven donor cell myeloid neoplasm (DCMN) cases (Figure 2). Among the altered genes, 27 variants in 26 strong candidates with oncogenic potential were found. This analysis showed 19 variants in genes associated with RNA processing and metabolism (LUC7L2, NOP14), cell differentiation (LAMA5, SKOR2, EML1), signal transduction (SNX13, IRS1, TENM2), including notch signaling pathway (NOTCH4, DTX1) and ERBB2 signaling pathway (GRB7), immunity regulator (MEFV), histone deacetylase (GSE1), DNA damage response (PNKP), post-translational modifications (SENP7), transcription factor (TAF1L, ZKSCAN2, ZNF461), and apoptotic process (MEGF10), as well as eight mutations in seven genes commonly found in adult acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (SETBP1, DNMT3A, TET2, RUNX1, CSF3R, EP300 and IDH2). All these mutations were confirmed by a customized targeted gene panel designed ad hoc to validate the variants selected in the WES which also included the most recurrent mutations in MN (Online Supplementary Appendix). By this approach, the gene panel analysis also allowed identification of mutations in CSF3R, NPM1, TP53 and ASXL1 genes (Online Supplementary Table S1).
Analysis of CNV revealed that the most common chromosomal alterations in DCMN were monosomy 7 (-7) or chromosome 7 abnormalities, which were detected in 6 out of 7 patients (Figure 2 and Online Supplementary Figures S3-S9).
Regarding the analysis performed on donor samples, copy number variation (CNV) analysis of stem cell apheresis from donor 1 revealed -7. Four years later, the recipient developed a donor cell myelodysplastic syndrome (DC-MDS), which showed -7 together with other molecular (SETBP1, LUC7L2) and cytogenetic alterations. This case highlights what has been described by other authors who suggested that SETBP1 mutations occur at later stages of disease evolution, influencing the clinical course of the disease rather than its initiation; they are associated with a poor prognosis.
The other six donors presented variants in genes that have been involved in hematologic or solid tumors: KLLN (c.445T>A), HOXD4 (c.242A>T), MSR1 (c.877C>T), HOXD12 (c.213T>C), MOS (c.426_432dupTGGCAAC), SETBP1 (c.3962G>A), MAD1L1 (c.851A>G).3,4,5,6,7 Of note, variants present in donor stem cells were also detected in all the corresponding follow-up samples after allo-SCT. Based on the variant allele frequency (VAF), all variants seem to have germline origin except for those in MOS (donor 5) and that in SETBP1 (donor 6), which appear be of somatic origin. Unfortunately, germline samples were not available to confirm this observation.
Interestingly, although acquired or inherited genetic alterations, which might be related to a predisposition to cancer, were observed in all donors, none of them had developed overt neoplasia at the moment of DCMN diagnosis in the recipients.
Considering the results in patients and donors described above, we propose a plausible model of leukemogenesis for each case, with progressive emergence of mutations in donor cells related to the development of AML or MDS after allo-HSCT (Figure 2). In cases 2, 4, 6 and 7, in which the median time to DCMN diagnosis was 21.5 months, the acquisition of mutations and the evolution of the leukemic clone occurs early after allo-HSCT, a period characterized by a marked immunosuppression state in the patients. Moreover, these four patients had received conditioning regimens based on chemotherapy combined with total body irradiation (TBI) and/or timoglobulin, which would also contribute to the development of MN.
The present study shows that MN evolve by an iterative process of genetic diversification derived from clonal selection and expansion that begin before the clinical onset, in accordance with the current multistep pathogenesis model of leukemogenesis.8 After the initiating mutation, malignant clones evolve and accelerate disease progression through the acquisition of new mutations. Although no clear pattern of clonal mutation acquisition has been observed, initiating mutations appear to affect epigenetic regulators of transcription (DNMT3A, TET2) or genes involved in intracellular signal transduction (SNX13, RHPN2, IRS1, CSF3R).
Different factors can influence the development of a neoplasm in donor cells. Interestingly, cytogenetic abnormalities involving chromosome 7 were the most frequent in our DCMN cohort (6 of 7 patients). The frequency of - 7 is particularly high among therapy or radiation-induced MDS or AML,9 as well as TP53 and epigenetic modifying gene somatic mutations,10 as in 4 out of 7 patients. In the present cohort, 6 of 7 patients received an alkylating agent or antimetabolites within the conditioning regimen. Furthermore, four of them also received ionizing radiation therapy, and the time of leukemogenic transformation in these patients was shorter than in those who only received chemotherapy. Due to the high prevalence of chromosome 7 anomalies in this entity (a characteristic previously observed by others authors2), it seems that the residual toxicity in the BM of prior chemotherapy and/or TBI plays an important role in pathophysiology of this disease. Of note, none of the donors had received chemotherapeutic or other toxic drugs.
Additionally, the post allo-HSCT period is characterized by a decreased immune surveillance caused by both conditioning regimens and by the immunosuppressive drugs administered to prevent graft-versus-host disease. Downregulation or inactivation of the immune system may facilitate malignant clonal progression. Consequently, the appearance or outgrowth of cells with potential to become cancerous is increased in this period.
Noteworthy, all seven donors in the present study had germline or acquired genetic alterations in genes which might be related to tumor development. Although some of the specific variants found in the donors have been described in low frequencies in particular human populations, all of them have also been previously described in families with a predisposition to cancer. Cancer-related genes usually show incomplete penetrance and variable expressivity, and need additional genomic events to lead to the development of a tumor.11 In this regard, post-SCT conditions might contribute to the progression of the phenotype. The existence of an acquired premalignant state bearing the initiating lesions has been reported in some donors who have no other signs of disease. Moreover, somatic mutations in genes involved in leukemogenesis were found in 5%, 10% and 20% of 60-, 70-, and 90-yearold individuals, respectively.12 Likewise, humans with clonal hematopoiesis have an increased risk of developing hematologic neoplasms compared with those without mutations.13 However, the use of older donors with clonal hematopoiesis of indeterminate potential (CHIP), otherwise revealed as a safe approach, has recently been associated with an increased risk of developing DCMN.14 Interestingly, CHIP-associated mutations were not found in any of the donors in our cohort, even though 5 of 7 were over 55 years old. This observation indicates that different mechanisms may be involved in the development of DCMN which would need further investigation.
Genetic predisposing factors are presumed to play an important role in the development of MN. Likewise, 16-21% of cancer survivors who developed t-MN have a germline mutation associated with inherited cancer susceptibility genes.15 It could be that individuals with germline mutations in these genes are particularly susceptible to cytotoxic chemotherapy and/or radiation.
The growing use of next-generation sequencing (NGS) to study gene panels to define patient prognosis or identify targetable genomic alterations would allow detection of germline variants with clinical significance in tumor samples. Identification of germline mutations in the recipient could rule out the variant in family members. Relatives with the mutation would not be considered as donors and would eventually be referred for genetic counseling.
In most cases reported in the literature, the donor has no evidence of MN development.2 Indeed, donors with such inherited molecular alterations do not necessarily develop leukemia, and they can live for many years without evidence of the disease, since other genetic or environmental factors, which are usually altered in transplanted patients, might play an important role in the development of malignant disease.
Presumably not just one mechanism from among those mentioned above is responsible for the leukemic transformation in donor cells. But a combination of various conditions would contribute to the development of DCMN after allo-HSCT. Such pre-leukemic stem cells from the donor might increase the likelihood that, later, co-operating mutations arise in cells that already contain the initiating mutations in a context of decreased immune surveillance. The relative contribution of each of the genetic and transplant-related factors to donor-derived leukemia is still not known. Novel approaches based on in-depth NGS to study consecutive samples from the post-transplant period in these patients appear promising to discover new genes involved in the development of MN and to decipher the ultimate mechanisms of leukemogenesis.
the present work was partially supported by the Ministry of Economy and Competitiveness ISCIII-FIS grants PI17/1880, cofinanced by ERDF (FEDER) Funds from the European Commission, “A way of making Europe”, as well as grants from the Asociación Madrileña de Hematología y Hemoterapia (AMHH), Asociación Española Contra el Cáncer (AECC) and Fundación Mutua Madrileña (FMM).
The authors are grateful to the patients and their families, as well as to the staff at Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute, La Princesa University Hospital, Puerta de Hierro University Hospital, Transfusion Centre of the Community of Madrid, Morales Meseguer General University Hospital and Spanish Group of Hematopoietic Transplantation (GETH). The authors wish to thank the biobanks at Puerta de Hierro University Hospital and Puerta de Hierro Health Research Institute (IDIPHIM) for some of the human specimens used in this study.
- Fialkow PJ, Thomas ED, Bryant JI, Neiman PE. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1971; 1(7693):251-255. https://doi.org/10.1016/S0140-6736(71)90998-6Google Scholar
- Suárez-González J, Martínez-Laperche C, Kwon M. Donor cell-derived hematologic neoplasms after hematopoietic stem cell transplantation: a systematic review. Biol Blood Marrow Transplant. 2018; 24(7):1505-1513. https://doi.org/10.1016/j.bbmt.2018.01.033PubMedGoogle Scholar
- Nizialek EA, Peterson C, Mester JL, Downes-Kelly E, Eng C. Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest. Hum Mol Genet. 2013; 22(12):2451-2461. https://doi.org/10.1093/hmg/ddt097PubMedPubMed CentralGoogle Scholar
- van Scherpenzeel Thim V, Remacle S, Picard J. Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. Hum Mutat. 2005; 25(4):384-395. https://doi.org/10.1002/humu.20155PubMedGoogle Scholar
- Xu J, Zheng SL, Komiya A. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 2002; 32(2):321-325. https://doi.org/10.1038/ng994PubMedGoogle Scholar
- Makishima H. Somatic SETBP1 mutations in myeloid neoplasms. Int J Hematol. 2017; 105(6):732-742. https://doi.org/10.1007/s12185-017-2241-1PubMedGoogle Scholar
- Tsukasaki K, Miller CW, Greenspun E. Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene. 2001; 20(25):3301-3305. https://doi.org/10.1038/sj.onc.1204421PubMedGoogle Scholar
- Ding L, Ley TJ, Larson DE. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481(7382):506-510. https://doi.org/10.1038/nature10738PubMedPubMed CentralGoogle Scholar
- McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017; 17(9):513-527. https://doi.org/10.1038/nrc.2017.60PubMedPubMed CentralGoogle Scholar
- Nishiyama T, Ishikawa Y, Kawashima N. Mutation analysis of therapy-related myeloid neoplasms. Cancer Genet. 2018; 222-223:38-45. https://doi.org/10.1016/j.cancergen.2018.02.006PubMedGoogle Scholar
- Suárez-González J, Martínez-Laperche C, Martínez N. Wholeexome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis. Leukemia. 2018; 32(8):1822-1826. https://doi.org/10.1038/s41375-018-0042-zPubMedGoogle Scholar
- Jaiswal S, Fontanillas P, Flannick J. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-2498. https://doi.org/10.1056/NEJMoa1408617PubMedPubMed CentralGoogle Scholar
- Genovese G, Kähler AK, Handsaker RE. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-2487. https://doi.org/10.1056/NEJMoa1409405PubMedPubMed CentralGoogle Scholar
- Frick M, Chan W, Arends CM. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019; 37(5):375-385. https://doi.org/10.1200/JCO.2018.79.2184PubMedGoogle Scholar
- Churpek JE, Marquez R, Neistadt B. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016; 122(2):304-311. https://doi.org/10.1002/cncr.29615PubMedPubMed CentralGoogle Scholar
Figures & Tables
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.